close
close

Mikael Dolsten, head of Pfizer’s R&D, steps down

FFive years ago — before the pandemic — Pfizer’s R&D chief, Mikael Dolsten, told STAT that he kept a chess set in his office that had been given to him as a gift by the company’s former CEO. It was a memento delivered to Dolsten after he warned his boss that R&D was a long process, like a game of chess, and not something that would happen quickly.

“I told him, look, this isn’t just one investment, it’s like a game of chess,” Dolsten said. “You have to have a picture of the whole opening game, win the middlegame and be really good in the endgame.”

On Tuesday, Dolsten reached the final.

STAT+ Exclusive Story

This article is available exclusively to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

See all plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe